{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=4",
    "query": {
      "condition": "Mild to Moderate Alzheimer's Disease",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 199,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mild+to+Moderate+Alzheimer%27s+Disease&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:46:36.555Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00930059",
      "title": "A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "PF-04447943",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 191,
      "start_date": "2009-09-10",
      "completion_date": "2010-09-22",
      "has_results": true,
      "last_update_posted_date": "2020-11-19",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 22,
      "location_summary": "Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more",
      "locations": [
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00930059"
    },
    {
      "nct_id": "NCT02006641",
      "title": "Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Idalopirdine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 858,
      "start_date": "2014-02",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 48,
      "location_summary": "Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Carson",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02006641"
    },
    {
      "nct_id": "NCT04124029",
      "title": "Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mild Traumatic Brain Injury",
        "Moderate Traumatic Brain Injury",
        "Mild Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan.",
          "type": "DEVICE"
        },
        {
          "name": "No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "30 Years to 90 Years"
      },
      "enrollment_count": 800,
      "start_date": "2021-07-01",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-16",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04124029"
    },
    {
      "nct_id": "NCT03493282",
      "title": "Effect of CT1812 Treatment on Brain Synaptic Density",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Active Treatment- CT1812 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Active Treatment- CT1812 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cognition Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 43,
      "start_date": "2018-03-28",
      "completion_date": "2020-10-16",
      "has_results": true,
      "last_update_posted_date": "2023-09-07",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03493282"
    },
    {
      "nct_id": "NCT01741194",
      "title": "AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AC-1204",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerecin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "66 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "66 Years to 90 Years"
      },
      "enrollment_count": 418,
      "start_date": "2013-03",
      "completion_date": "2017-04-14",
      "has_results": false,
      "last_update_posted_date": "2021-08-02",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01741194"
    },
    {
      "nct_id": "NCT00506415",
      "title": "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 5 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 10 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 15 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 15 cm^2 patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 10 cm^2 patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 1584,
      "start_date": "2007-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506415"
    },
    {
      "nct_id": "NCT01193608",
      "title": "Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "AAB-003 (PF-05236812)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "50 Years to 89 Years"
      },
      "enrollment_count": 88,
      "start_date": "2010-09",
      "completion_date": "2013-10",
      "has_results": true,
      "last_update_posted_date": "2017-02-23",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 23,
      "location_summary": "Escondido, California • Hallandale, Florida • Ocala, Florida + 11 more",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01193608"
    },
    {
      "nct_id": "NCT00142805",
      "title": "Tricaprilin in Mild to Moderate Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Tricaprilin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Cerecin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 152,
      "start_date": "2004-11-04",
      "completion_date": "2007-01-07",
      "has_results": false,
      "last_update_posted_date": "2020-09-21",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142805"
    },
    {
      "nct_id": "NCT01549834",
      "title": "Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ABT-126",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 434,
      "start_date": "2012-03",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-10-31",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 11,
      "location_summary": "Fresno, California • Long Beach, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Delray Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01549834"
    },
    {
      "nct_id": "NCT01795339",
      "title": "A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Elderly Volunteers",
        "Mild-to-moderate Alzheimer's Disease Patients"
      ],
      "interventions": [
        {
          "name": "AZD3293",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 47,
      "start_date": "2013-03",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2014-04-03",
      "last_synced_at": "2026-11-19T06:46:36.555Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01795339"
    }
  ]
}